ATE225660T1 - Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz - Google Patents

Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz

Info

Publication number
ATE225660T1
ATE225660T1 AT98912108T AT98912108T ATE225660T1 AT E225660 T1 ATE225660 T1 AT E225660T1 AT 98912108 T AT98912108 T AT 98912108T AT 98912108 T AT98912108 T AT 98912108T AT E225660 T1 ATE225660 T1 AT E225660T1
Authority
AT
Austria
Prior art keywords
cyclooxygenase
inhibitors
treat
prevent dementia
dementia
Prior art date
Application number
AT98912108T
Other languages
English (en)
Inventor
Philip Needleman
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of ATE225660T1 publication Critical patent/ATE225660T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98912108T 1997-04-03 1998-03-30 Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz ATE225660T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4391697P 1997-04-03 1997-04-03
PCT/US1998/006143 WO1998043648A1 (en) 1997-04-03 1998-03-30 Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia

Publications (1)

Publication Number Publication Date
ATE225660T1 true ATE225660T1 (de) 2002-10-15

Family

ID=21929578

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98912108T ATE225660T1 (de) 1997-04-03 1998-03-30 Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz

Country Status (12)

Country Link
EP (1) EP0971714B1 (de)
JP (1) JP2002514208A (de)
AT (1) ATE225660T1 (de)
AU (1) AU725697B2 (de)
BR (1) BR9807920A (de)
CA (1) CA2285434A1 (de)
DE (1) DE69808607T2 (de)
DK (1) DK0971714T3 (de)
ES (1) ES2185154T3 (de)
PT (1) PT971714E (de)
WO (1) WO1998043648A1 (de)
ZA (1) ZA982808B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727238B2 (en) 1998-06-11 2004-04-27 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US6294558B1 (en) 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420616D0 (en) * 1994-10-12 1994-11-30 Merck Sharp & Dohme Method, compositions and use
RO118291B1 (ro) * 1993-11-30 2003-04-30 Searle & Co Derivati de pirazol 1,3,4,5 - tetrasubstituiti si compozitie farmaceutica care ii contine
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US5547975A (en) * 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
US5696143A (en) * 1994-09-20 1997-12-09 Talley; John J. Benz G! indazolyl derivatives for the treatment of inflammation
WO1996038418A1 (en) * 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
WO1996041626A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
CA2224563A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
WO1997038986A1 (en) * 1996-04-12 1997-10-23 G.D. Searle & Co. Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors

Also Published As

Publication number Publication date
WO1998043648A1 (en) 1998-10-08
JP2002514208A (ja) 2002-05-14
DE69808607T2 (de) 2003-06-26
EP0971714A1 (de) 2000-01-19
DK0971714T3 (da) 2002-11-04
EP0971714B1 (de) 2002-10-09
AU6590498A (en) 1998-10-22
CA2285434A1 (en) 1998-10-08
BR9807920A (pt) 2000-02-22
DE69808607D1 (de) 2002-11-14
ZA982808B (en) 1999-04-06
PT971714E (pt) 2002-12-31
AU725697B2 (en) 2000-10-19
ES2185154T3 (es) 2003-04-16
HK1024872A1 (en) 2000-10-27

Similar Documents

Publication Publication Date Title
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE399547T1 (de) Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und vorbeugung von neoplasia
ATE242632T1 (de) Verwendung von betulinsäure-derivaten zur behandlung und vorbeugung von melanomen
DE69427869D1 (de) Botulinumtoxine zur behandlung von hyperhydrosis
ATE217865T1 (de) Verbindungen zur hemmung von phosphodiesrerase iv
ATE250932T1 (de) Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
ATE278399T1 (de) Orotatsalze von 5-amino- oder substituierten amino-1,2,3-triazolen zur behandlung von neoplasmen
ATE128143T1 (de) 17-beta-substituierte-4-aza-5-alpha-androstan-3 one-derivate und verfahren zu ihrer herstellung.
DE69603089D1 (de) Zusammensetzung zur behandlung von mauerwerk
ATE301995T1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE259640T1 (de) Verwendung von matrix-metalloproteinase inhibitoren zur förderung der wundheilung
SE9602263D0 (sv) New amino acid derivatives
DE69433793D1 (de) Phosphorderivate zur behandlung von aids
EP0758894A4 (de) Verwendung von alpha-1c spezifischen verbindungen zur behandlung der benignen prostatahyperplasie
ATE232191T1 (de) Verfahren und zusammensetzung zur inhibierung der polymerisierung von ethylenisch ungesättigten kohlenwasserstoffen
DE69718347D1 (de) VERWENDUNG EINER ZUSAMMENSETZUNG AUS H+, K+ -ATPase-INHIBITOREN UND GLUCOCORTIKOIDEN ZUR BEHANDLUNG VON NASENPOLYPEN
DE69937624D1 (de) Verfahren zur Behandlung von Metalloberflächen
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
DE59209268D1 (de) Verfahren zur thermochemisch-thermischen behandlung von einsatzstählen
DE69228814D1 (de) Verfahren zur vorbeugung und behandlung von durch chemotherapie ausgelöster alopezie
DE69330465D1 (de) Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4-aza-5 alpha-androst-1-en-3-one
DE69808607D1 (de) Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz
ATE267018T1 (de) Verwendung von peptidverbindungen zur behandlung von sle
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
DE59904564D1 (de) Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0971714

Country of ref document: EP

REN Ceased due to non-payment of the annual fee